Takeda Pharmaceutical Co. Ltd.'s next confirmed earnings release is scheduled for January 28, 2027.
| Earnings Date | 1/28/2027 |
As of September 30, 2026, Takeda Pharmaceutical Co. Ltd. has 1.60B shares outstanding.
| Shares Outstanding | 1.60B |
As of September 30, 2026, Takeda Pharmaceutical Co. Ltd. maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.69, indicating elevated leverage, while an interest coverage ratio of 9.89 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.15 |
| Quick Ratio | 0.52 |
| Debt / Equity | 61.69 |
| Debt / EBITDA | 5.44 |
| Interest Coverage | 9.89 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co. Ltd. posted a return on equity (ROE) of 0.56, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.27, measuring how efficiently the asset base is converted into earnings. The company generates approximately 99.57M in revenue per employee across its workforce of 47,135.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.17 indicates how many times Takeda Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 0.56 |
| Return on Assets (ROA) | 0.27 |
| Revenue Per Employee | 99.57M |
| Employee Count | 47,135.50 |
| Inventory Turnover | 1.17 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co. Ltd. recorded an income tax benefit of -43.51B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.47B and 40.80B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -43.51B |
As of the close on November 4, 2026, Takeda Pharmaceutical Co. Ltd.'s stock has gained approximately 44.40% over the past 52 weeks.
| 52-Week Price Change | 44.40% |
| 50-Day Moving Average | 4,168.00 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co. Ltd. generated 4.69T in revenue and converted that into 40.80B in net income, yielding earnings per share of 25.63. EBITDA reached 841.38B, while operating income came in at 697.45B.
| Revenue | 4.69T |
| Gross Profit | 3.09T |
| Operating Income | 697.45B |
| Pretax Income | -2.47B |
| Net Income | 40.80B |
| EBITDA | 841.38B |
| EBIT | 159.40B |
| Earnings Per Share (EPS) | 25.63 |
As of September 30, 2026, Takeda Pharmaceutical Co. Ltd. holds 454.40B in cash and equivalents against 4.58T in total debt, resulting in a net debt position of 4.16T. Total book value stands at 7.42T, with working capital of 393.61B providing operational flexibility.
| Cash & Cash Equivalents | 454.40B |
| Total Debt | 4.58T |
| Net Debt | 4.16T |
| Equity (Book Value) | 7.42T |
| Book Value Per Share | 4,642.52 |
| Working Capital | 393.61B |
Takeda Pharmaceutical Co. Ltd. produced 879.67B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -445.72B in capital expenditures, free cash flow totaled 433.95B - equivalent to 274.16 per share.
| Operating Cash Flow | 879.67B |
| Capital Expenditures | -445.72B |
| Free Cash Flow | 433.95B |
| FCF Per Share | 274.16 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co. Ltd. posted a gross margin of 65.79, reflecting its pricing power and cost economics. The operating margin of 14.86 and net profit margin of 0.87 provide insight into operational efficiency.
| Gross Margin | 65.79 |
| Operating Margin | 14.86 |
| Pretax Margin | -0.05 |
| Profit Margin | 0.87 |
| EBITDA Margin | 17.93 |
Over the twelve months ended September 30, 2026, Takeda Pharmaceutical Co. Ltd. paid dividends of 199.45 per share. The dividend payout ratio of 764.63 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.
| Dividend Per Share | 199.45 |
| Payout Ratio | 764.63 |
Takeda Pharmaceutical Co. Ltd.'s most recent stock split took place on March 28, 1988 with a 10:11 split ratio.
| Last Split Date | 3/28/1988 |
| Split Ratio | 10:11 |
Already premium?